Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.68 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.67 |
| ▸ | FABP4 | P15090 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391834 | 1.00 | AKR1C3 (0.68) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL9592803 | 0.87 | AKR1C3 (0.76) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL9595564 | 0.87 | AKR1C3 (0.74) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL8390874 | 0.87 | AKR1C3 (0.71) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL11335085 | 0.87 | TAS2R14 (0.74) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL7852387 | 0.84 | MAPT (0.71) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL4222620 | 0.84 | AKR1C3 (0.66) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL23706794 | 0.83 | AKR1C3 (0.52) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL17208131 | 0.83 | AKR1C3 (0.52) | AKR1C3AKR1C2AURKAMAPK8AURKB | |
| SCHEMBL31150705 | 0.83 | AKR1C3 (0.69) | AKR1C3AKR1C2AURKAMAPK8AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339236-A1 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-10-27 | — | — | US | claimed |
| EP-4034097-A2 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE MRNAS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2022-08-03 | — | — | EP | claimed |
| WO-2021059270-A2 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-04-01 | — | — | WO | claimed |
| CN-119731146-A | (2, 4-Dichlorophenoxy) acetic acid analogues | 科迪华农业科技有限责任公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-117813004-A | Auxin herbicide and application method thereof | 科迪华农业科技有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20220339236-A1 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-10-27 | — | — | US | disclosed |
| EP-4034097-A2 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE MRNAS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2022-08-03 | — | — | EP | disclosed |
| US-20210311075-A1 | METHODS FOR DETECTING DISORDERS RELATED TO CALCIUM DISCHARGE FROM INTRACELLULAR STORES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021155195-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, NEURODEVELOPMENTAL, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS | GEORGETOWN UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021059270-A2 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-04-01 | — | — | WO | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160082132-A1 | COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MAGNETIC RESONANCE IMAGING (MRI) | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-24 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2013096153-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-7888509-B2 | Chiral 1,8-diarylnaphthalenes, methods of making them, and their use as sensors | GEORGETOWN UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070276140-A1 | Chiral 1,8-Diarylnaphthalenes, Methods of Making Them, and Their Use as Sensors | GEORGETOWN UNIVERSITY (US) | 2007-11-29 | — | — | US | disclosed |
| US-4273873-A | BONDING SYNTHETIC FIBRINOLYTIC COMPOUND OR ENZYME | UNITIKA LTD. (JP) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | AKR1C3 1497/4885AKR1C2 1258/4885AURKA 4645/4885 |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | AKR1C3 712/4885AKR1C2 945/4885AURKA 1752/4885 |
| US-20160082132-A1 | COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MAGNETIC RESONANCE IMAGING (MRI) | GART, SLC43A1, AADAT | AKR1C3 867/4885AKR1C2 779/4885AURKA 2818/4885 |
| US-20070276140-A1 | Chiral 1,8-Diarylnaphthalenes, Methods of Making Them, and Their Use as Sensors | ALKBH2, ALKBH1, ALG3 | AKR1C3 447/4885AKR1C2 414/4885AURKA 784/4885 |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | TTR, TTPA, APOB | AKR1C3 712/4885AKR1C2 945/4885AURKA 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.